More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
EXTON, Pa., April 10, 2018 -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that John Maslowski, President and Chief Executive Officer, will present at the Alliance for Regenerative Medicine’s (ARM) 6th Annual Cell & Gene Therapy Investor Day on Tuesday, April 17 at 12:10 pm EDT in New York City and at the 2018 World Orphan Drug Congress USA on Wednesday, April 25 at 2:00 pm EDT in Oxon Hill, Maryland.
A live webcast of Fibrocell’s presentation at ARM’s Cell & Gene Therapy Investor Day will be available under the investor relations section of the Company’s website at www.fibrocell.com/investors/events and archived for 30 days.
About Fibrocell
Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs for diseases affecting the skin and connective tissue. Fibrocell’s most advanced product candidate, FCX-007, is the subject of a Phase 1/2 trial for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell is also developing FCX-013, the Company’s product candidate for the treatment of moderate to severe localized scleroderma. Fibrocell’s gene therapy portfolio is being developed in collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology. For more information, visit http://www.fibrocell.com or follow Fibrocell on Twitter at @Fibrocell.
Trademarks
Fibrocell, the Fibrocell logo and Fibrocell Science are trademarks of Fibrocell Science, Inc. and/or its affiliates. All other names may be trademarks of their respective owners.
Investor & Media Relations Contact:
Karen Casey
484.713.6133
[email protected]
